Which companies overlap with Vascular Biogenics Ltd. operating as VBL Therapeutics's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/vascular-biogenics-ltd-operating-as-vbl-therapeutics.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Vascular Biogenics Ltd. operating as VBL Therapeutics — Portfolio Competitive Intelligence Brief

Vascular Biogenics Ltd. operating as VBL Therapeutics pipeline: 0 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
VB-111 + bevacizumab	VB-111 + bevacizumab	phase 3	Antiangiogenic agent	VEGF	Oncology
VB-111 + Paclitaxel	VB-111 + Paclitaxel	phase 3	VEGF aptamer and microtubule inhibitor	VEGF	Oncology

Therapeutic area mix

Oncology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Vascular Biogenics Ltd. operating as VBL Therapeutics:

Cite this brief

Drug Landscape (2026). Vascular Biogenics Ltd. operating as VBL Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vascular-biogenics-ltd-operating-as-vbl-therapeutics. Accessed 2026-05-16.